July 14, 2016
Researchers at the University of North Carolina at Chapel Hill will receive nearly $23 million over the next five years to continue research on their innovative “kick and kill” strategy for eradicating HIV. Worldwide, 37 million people are living with the virus.
After a competitive application process, the National Institutes of Health (NIH) selected the UNC-based Collaboratory of AIDS Researchers for Eradication (CARE) for refunding. David Margolis, MD, professor of epidemiology at UNC’s Gillings School of Global Public Health and of medicine in the UNC School of Medicine, is CARE’s principal investigator.
“I think we were refunded for several reasons,” Margolis said. “As we seek both to do discovery science and progress new therapies, our long-standing collaboration with Merck was extremely productive. We have now developed a new and unique partnership with GlaxoSmithKline (GSK), which resulted in Qura Therapeutics. New work with leaders in innovative therapeutics such as MacroGenics also has shown great promise. Along those lines, a powerful addition to our academic team has been new partnerships with the Duke Human Vaccine Institute and the Yerkes National Primate Research Center at Emory. These give us new tools to study viral persistence and clearance.”
The National Institute of Allergy and Infectious Diseases, part of the NIH, first funded CARE in 2011 through its Martin Delaney Collaboratory program for HIV cure research. The program was the first major funding initiative to focus on eradication of HIV from the body and was named in honor of internationally recognized HIV activist Martin Delaney.
The UNC-led group includes partners at other universities around the country focusing on the “kick and kill” strategy for curing HIV. This approach involves waking up the latent or sleeping virus in the body and boosting the immune system to then recognize and clear the virus.
CARE will continue to study this strategy for eradicating HIV, bolstered by what the researchers have learned over the past five years.
“The last five years have allowed us to develop the HIV cure field and understand more about viral latency – the strengths and weaknesses of measuring it, how to reverse it, and the need to combine latency reversing agents with strategies to clear the infection,” said Margolis. “Over the next five years, we will develop better ways to detect, measure and reverse latency. We will find ways to pair latency reversal with clearance of the virus – because these two parts of the strategy must work together – and we will accelerate the evaluation of these approaches in animal models and humans.”
Finding a cure for HIV is one of several tools that can build an AIDS-free generation. CARE’s researchers and Community Advisory Board (CAB) members agree that to truly eliminate the global burden of HIV, prevention, treatment and cure initiatives must align.
“We know about treatment, and we know about prevention, but cure is a new frontier,” said Erik Valera, co-chair of the CARE CAB and program director for the Latino Commission on AIDS, a nonprofit organization founded in 1990 to stop the spread of HIV/AIDS in the Latino community. “We need to keep the community engaged in HIV cure research. It is important we educate the community members about this science. We should all be hopeful, yet realistic, regarding a cure for HIV.”
For more information about CARE, visit delaneycare.org.
This news originally was posted by the UNC Institute for Global Health and Infectious Diseases.